January 14, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Cios Flow, a mobile C-arm designed for use by multiple disciplines in the operating room (OR) – including orthopedics, trauma surgery, spinal surgery, vascular surgery, and pain therapy – to increase the ease and efficiency of everyday imaging workflows for surgical interventions.

January 13, 2021 — Use of telehealth jumped sharply during the first months of the coronavirus pandemic shutdown, with the approach being used more often for behavioral health services than for medical care, according to a new RAND Corporation study.

January 13, 2021 — DenseBreast-info.org (DB-I) invites health providers seeking the most up-to-date medically-sourced educational materials about the screening and risk implications of dense breast tissue and value of supplemental screening to visit the newly re-launched DB-I website at www.DenseBreast-info.org.

January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received FDA clearance for commercial sales in the United States in March 2020, this artificial intelligence (AI) solution is now available in the European market.

January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

January 11, 2021 — In a letter published in the December issue of the American Heart Association's medical journal Circulation a group of researchers at Vanderbilt University Medical Center (VUMC) dispute the most recent findings of the incidence of myocarditis in athletes with a history of

January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s disease symptoms that are much more severe on one side of the body, new research suggests.

More testing is needed, but the approach, which uses a technology called focused ultrasound, could offer a new option for patients whose symptoms are poorly controlled by medications and those who cannot or do not wish to undergo traditional brain surgery.

January 8, 2021 — The U.S. Food and Drug Administration is alerting clinical laboratory staff and healthcare providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus’s genome assessed by that test.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now